Long-term vaccine-induced heterologous protection against H5N1 influenza viruses in the ferret model

Influenza and other Respiratory Viruses

Volumn 7, Issue 4, 2013, Pages 506-512

  Ducatez, Mariette F ^a,b   Webb, Ashley ^a   Crumpton, Jeri Carol ^a   Webby, Richard J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Ferret; H5N1; Influenza virus; Pandemic; Vaccine

Indexed keywords

INFLUENZA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; FERRET; HEMAGGLUTININ GENE; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MALE; MORBIDITY; MORTALITY; NEURAMINIDASE GENE; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; VIRUS STRAIN;

ANIMALS; BODY TEMPERATURE; BODY WEIGHT; CROSS PROTECTION; DISEASE MODELS, ANIMAL; FERRETS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MALE; NASAL CAVITY; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VACCINES, INACTIVATED; VIRAL LOAD;

EID: 84879098748     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2012.00423.x     Document Type: Article

References (33)

1. Yen HL, Webster RG. Pandemic influenza as a current threat. Curr Top Microbiol Immunol 2009; 333:3-24.
2. Xu X, Subbarao K, Cox NJ, Guo Y. Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology 1999; 261:15-19.
3. World Organization for Animal Health. Update on highly pathogenic avian influenza in animals (type H5 and H7). Available at http://www.oie.int/downld/AVIAN%20INFLUENZA/A_AI-Asia.htm (Accessed 6 February 2012).
4. World Health Organization. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. 2011. Available at http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/index.html (Accessed 6 February 2012).
5. Donis RO, Smith GJ, Perdue ML et al. Toward a unified nomenclature system for highly pathogenic avian influenza virus (H5N1). Emerg Infect Dis 2008; 14:e1.
6. World Health Organization. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses for development of candidate vaccines viruses for pandemic preparedness - February 2011. Wkly Epidemiol Rec 2011; 86:93-100.
7. Govorkova EA, Webby RJ, Humberd J, Seiler JP, Webster RG. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 2006; 194:159-167.
8. Ducatez MF, Bahl J, Griffin Y et al. Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development. Proc Natl Acad Sci USA 2011; 108:349-354.
9. Lipatov AS, Hoffmann E, Salomon R, Yen HL, Webster RG. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis 2006; 194:1040-1043.
10. Hoschler K, Gopal R, Andrews N et al. Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains. Influenza Other Respi Viruses 2007; 1:199-206.
11. Levie K, Leroux-Roels I, Hoppenbrouwers K et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008; 198:642-649.
12. Lu X, Edwards LE, Desheva JA et al. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 2006; 24:6588-6593.
13. Suguitan AL Jr, McAuliffe J, Mills KL et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006; 3:e360.
14. Baras B, Stittelaar KJ, Kuiken T et al. Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets. Vaccine 2011; 29:2092-2099.
15. Middleton D, Rockman S, Pearse M et al. Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J Virol 2009; 83:7770-7778.
16. Quan FS, Huang C, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 2007; 81:3514-3524.
17. Schwartz JA, Buonocore L, Suguitan AL Jr et al. Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge. J Virol 2010; 84:4611-4618.
18. Wood JS, Robertson JS. Reference viruses for seasonal and pandemic influenza vaccine preparation. Influenza Other Respi Viruses 2007; 1:5-9.
19. Abelin A, Colegate T, Gardner S, Hehme N, Palache A. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective. Vaccine 2011; 29:1135-1138.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
21. World Health Organization. WHO manual on animal diagnosis and surveillance. 2011. Available at http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf (Accessed 21 October 2011).
22. Reed LJ, Muench H. A simple method for estimating fifty percent endpoints. Am J Hyg 1938; 27:493-497.
23. Goji NA, Nolan C, Hill H et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 2008; 198:635-641.
24. Stephenson I, Bugarini R, Nicholson KG et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005; 191:1210-1215.
25. Leroux-Roels I, Roman F, Forgus S et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010; 28:849-857.
26. Lin JT, Li CG, Wang X et al. Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine. J Infect Dis 2009; 199:184-187.
27. Nguyen HH, van Ginkel FW, Vu HL, McGhee JR, Mestecky J. Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis 2001; 183:368-376.
28. Crowe BA, Brühl P, Gerencer M et al. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. Vaccine 2010; 29:166-173.
29. Roti M, Yang J, Berger D, Huston L, James EA, Kwok WW. Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J Immunol 2008; 180:1758-1768.
30. Lee LY, Ha do LA, Simmons C et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 2008; 118:3478-3490.
31. Goy K, Von Bibra S, Lewis J et al. Heterosubtypic T-cell responses against avian influenza H5 haemagglutinin are frequently detected in individuals vaccinated against or previously infected with human subtypes of influenza. Influenza Other Respi Viruses 2008; 2:115-125.
32. Dormitzer PR, Galli G, Castellino F et al. Influenza vaccine immunology. Immunol Rev 2011; 239:167-177.
33. LaMere MW, Lam HT, Moquin A et al. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol 2011; 186:4331-4339.